Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia
Published in November 19th, 2008
Comments Off
KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction
Published in November 19th, 2008
Comments Off
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
Published in November 19th, 2008
Comments Off
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.
Metabolex announces positive results from phase 2 trial of MBX-8025
Published in November 19th, 2008
Comments Off
The Phase 2 study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor(R)), over an 8-week treatment period.
Call for greater scrutiny of relationship between medical journalists and health care industry
Published in November 19th, 2008
Comments Off
The BMJ paper outlines three areas where journalists might become entangled in conflict-of-interest issues: during educational activities that may be drug company sponsored, when accepting sponsored awards, or in the day-to-day practice of reporting the news by relying too heavily on industry supplied sources.
XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
Published in November 19th, 2008
Comments Off
XTL Biopharmaceuticals Ltd. ( NASDAQ:XTLB ) announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain.
Viral Genetics, Inc. Completes Acquisition of V-Clip Pharmaceuticals,
Published in November 19th, 2008
Comments Off
Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today announced it has completed its acquisition of V-Clip Pharmaceuticals, Inc. (“V-Clip”).
Roche NimbleGen Launches CGH 12×135K Microarrays for Detection of Copy
Published in November 19th, 2008
Comments Off
Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12×135K format for analysis of DNA copy number variation.
KAI Reports Positive Preclinical Results for KAI-1678, First-in-Class
Published in November 19th, 2008
Comments Off
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Published in November 19th, 2008
Comments Off
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).